Major Depressive Disorder Clinical Trial
Official title:
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX
Objective:
Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to
glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby
fine-tuning the signals sent between cells to maintain balance in neuronal activity. mGluR
subtype 1 (mGluR1s) are located in several brain regions, including the cerebellum,
hippocampus, olfactory bulb, and basal ganglia. mGluR1 activation stimulates phospholipase C,
resulting in phosphoinositide hydrolysis and increased intracellular calcium levels.
Successful development of a positron emission tomography (PET) ligand to image mGlurR1 would
impact clinical management of brain disorders characterized by disruptions in glutamatergic
transmission, including anxiety and stress disorders, drug addiction, epilepsy, Huntington s
disease, and Parkinson s disease. However, detailed study of mGluR1s has heretofore been
hindered by the lack of high affinity and selective ligands for this receptor subtype.
The present protocol will evaluate the ability of a new PET ligand, [18F]FIMX, to image and
quantify mGluR1 in the brain of healthy human volunteers. This protocol covers four phases:
1. Phase 0: screening whole-body scan;
2. Phase 1: kinetic brain imaging to quantify mGluR1 in brain relative to concurrent
measurement of the parent radioligand in arterial plasma;
3. Phase 2: if the tracer is successful in Phase 1, we will estimate radiation-absorbed
doses of [18F]FIMX by performing whole body imaging;
4. Phase 3: test-retest analysis of brain binding relative to concurrent measurement of the
parent radioligand in arterial plasma.
Study Population:
Healthy adult female and male volunteers (n=22, ages 18 to 55) will undergo brain or
whole-body imaging..
Design:
This study will begin with a screening whole-body scan to confirm that the radioactivity has
fairly broad distribution in several organs. For absolute quantification of mGluR1, 22
healthy controls will have brain PET imaging using [18F]FIMX and an arterial line. Up to 12
of them will have a test-retest scan. Eight additional subjects will have a whole body PET
scan for dosimetry, which does not require an arterial line.
<TAB>
Outcome Measures
To assess absolute quantitation of mGluR1 with [18F]FIMX, we will primarily use two outcome
measures: the identifiability and time stability of distribution volume calculated with
compartmental modeling. In test-retest study, we will calculate the retest variability. To
assess whole-body biodistribution and dosimetry of [18F]FIMX we will use the organ
time-activity curves....
Objective:
Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that respond to
glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby
fine-tuning the signals sent between cells to maintain balance in neuronal activity. mGluR
subtype 1 (mGluR1s) are located in several brain regions, including the cerebellum,
hippocampus, olfactory bulb, and basal ganglia. mGluR1 activation stimulates phospholipase C,
resulting in phosphoinositide hydrolysis and increased intracellular calcium levels.
Successful development of a positron emission tomography (PET) ligand to image mGlurR1 would
impact clinical management of brain disorders characterized by disruptions in glutamatergic
transmission, including anxiety and stress disorders, drug addiction, epilepsy, Huntington s
disease, and Parkinson s disease. However, detailed study of mGluR1s has heretofore been
hindered by the lack of high affinity and selective ligands for this receptor subtype.
The present protocol will evaluate the ability of a new PET ligand, [18F]FIMX, to image and
quantify mGluR1 in the brain of healthy human volunteers. This protocol covers four phases:
1. Phase 0: screening whole-body scan;
2. Phase 1: kinetic brain imaging to quantify mGluR1 in brain relative to concurrent
measurement of the parent radioligand in arterial plasma;
3. Phase 2: if the tracer is successful in Phase 1, we will estimate radiation-absorbed
doses of [18F]FIMX by performing whole body imaging;
4. Phase 3: test-retest analysis of brain binding relative to concurrent measurement of the
parent radioligand in arterial plasma.
Study Population:
Healthy adult female and male volunteers (n=22, ages 18 to 55) will undergo brain or
whole-body imaging.
Design:
This study will begin with a screening whole-body scan to confirm that the radioactivity has
fairly broad distribution in several organs. For absolute quantification of mGluR1, 22
healthy controls will have brain PET imaging using [18F]FIMX and an arterial line. Up to 12
of them will have a test-retest scan. Eight additional subjects will have a whole body PET
scan for dosimetry, which does not require an arterial line.
<TAB>
Outcome Measures
To assess absolute quantitation of mGluR1 with [18F]FIMX, we will primarily use two outcome
measures: the identifiability and time stability of distribution volume calculated with
compartmental modeling. In test-retest study, we will calculate the retest variability. To
assess whole-body biodistribution and dosimetry of [18F]FIMX we will use the organ
time-activity curves.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |